Developing Novel Cancer Drugs by Targeting Metabolism
ImmunoMet Therapeutics is a clinical-stage oncology company developing lixumistat (IM156) — a first-in-class OxPhos inhibitor targeting the metabolic dependency that drives cancer cell survival in resistant tumours.
Clinical Stage — Pancreatic Cancer
Lead Asset (IM156)
Total Capital Raised, 2015–present
Asset Status
When cancer cells develop resistance to standard treatments, many rewire their metabolism to depend on oxidative phosphorylation for energy.
Lixumistat targets this dependency directly — exploiting a vulnerability that resistant tumours create for themselves.
The Phase 1b/2a trial at MD Anderson has shown encouraging early results. 5 clinical responses in 10 evaluable patients at the recommended Phase 2 dose.
Disease control rate 80%. Presented at ASCO GI (January 2025) and ESMO GI (July 2025).
The Phase 1b/2a trial at MD Anderson has shown encouraging early results. 5 clinical responses in 10 evaluable patients at the recommended Phase 2 dose. Disease control rate 80%. Presented at ASCO GI (January 2025) and ESMO GI (July 2025).
Developing Novel Cancer Drugs by Targeting Metabolism. ImmunoMet Therapeutics, Inc.
Science & Clinical
Investors
Company
Houston, Texas
